National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Drug Events (ADE) (1)
- Antibiotics (1)
- Asthma (1)
- Behavioral Health (3)
- Children/Adolescents (3)
- Comparative Effectiveness (2)
- COVID-19 (1)
- Diabetes (1)
- Electronic Health Records (EHRs) (1)
- Evidence-Based Practice (3)
- Healthcare-Associated Infections (HAIs) (1)
- Healthcare Costs (1)
- Health Information Technology (HIT) (1)
- Human Immunodeficiency Virus (HIV) (1)
- Infectious Diseases (1)
- Medicaid (1)
- Medical Expenditure Panel Survey (MEPS) (1)
- (-) Medication (16)
- (-) Obesity (16)
- Obesity: Weight Management (5)
- Opioids (3)
- Outcomes (4)
- Pain (3)
- Patient-Centered Outcomes Research (2)
- Patient Safety (1)
- Policy (1)
- Prevention (1)
- Quality Improvement (1)
- Quality Measures (1)
- Quality of Care (1)
- Risk (1)
- Substance Abuse (2)
- Surgery (6)
- Treatments (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 16 of 16 Research Studies DisplayedLiu S, Matvekas A, Naimi T
Morphomics-informed population pharmacokinetic and physiologically-based pharmacokinetic modeling to optimize cefazolin surgical prophylaxis.
This study’s objective was to use algorithms that repurpose radiologic data into body composition (morphomics) to aid in informing dosing decisions for the antibiotic cefazolin for patients undergoing colorectal surgery who have obesity. This prospective study measured cefazolin plasma, fat, and colon tissue concentrations in these patients to develop a morphomics-informed population pharmacokinetic (PopPK) model to guide dose adjustments. A physiologically-based pharmacokinetic (PBPK) model was also constructed to inform tissue partitioning in 21 morbidly obese patients (body mass index ≥35 kg/m2 with one or more co-morbid conditions). Morphomics and pharmacokinetic data were available in 58 patients with a median weight of 95.9 kg and and 55 years, respectively. The plasma-to-subcutaneous fat partition coefficient was predicted to be 0.072 for the PopPK model and 0.060 for the PBPK model. Covariates of cefazolin exposure were identified as the estimated creatinine clearance (eCL(cr) ) and body depth at the third lumbar vertebra (body depth_L3). The authors concluded that kidney function and morphomics were more informative than body weight as covariates of cefazolin target site exposure. They advised that data from more diverse populations, consensus on target cefazolin exposure, and comparative studies are needed before a change in practice can be implemented.
AHRQ-funded; HS027183.
Citation: Liu S, Matvekas A, Naimi T .
Morphomics-informed population pharmacokinetic and physiologically-based pharmacokinetic modeling to optimize cefazolin surgical prophylaxis.
Pharmacotherapy 2024 Jan; 44(1):77-86. doi: 10.1002/phar.2878..
Keywords: Surgery, Antibiotics, Medication, Prevention, Obesity, Healthcare-Associated Infections (HAIs)
Huo T, Li Q, Cardel MI
AHRQ Author: Mistry K
Enhancing quality measurement with clinical information: a use case of body mass index change among children taking second generation antipsychotics.
The authors sought to examine the extent to which body mass index (BMI) was available in electronic health records for Florida Medicaid recipients aged 5 to 18 years taking Second-Generation Antipsychotics (SGAP). They concluded that meeting the 2030 CMS goal of digital monitoring of quality of care will require continuing expansion of clinical encounter data capture to provide the data needed for digital quality monitoring. Using linked electronic health records and claims data allows identifying children at higher risk for SGAP-induced weight gain.
AHRQ-authored; AHRQ-funded; HS025298.
Citation: Huo T, Li Q, Cardel MI .
Enhancing quality measurement with clinical information: a use case of body mass index change among children taking second generation antipsychotics.
Acad Pediatr 2022 Apr;22(3S):S140-S49. doi: 10.1016/j.acap.2021.11.012..
Keywords: Children/Adolescents, Electronic Health Records (EHRs), Health Information Technology (HIT), Medication, Obesity, Obesity: Weight Management, Quality Measures, Quality of Care
Howard R, Chao GF, Yang J
Medication use for obesity-related comorbidities after sleeve gastrectomy or gastric bypass.
The purpose of this comparative effectiveness research study was to evaluate prior laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass patients and compare the incidence of medication discontinuation and restart of diabetes, hypertension, and hyperlipidemia medications. The researchers reviewed the records of adult Medicare beneficiaries who underwent sleeve gastrectomy or gastric bypass between January 1, 2012, to December 31, 2018, and had a claim for diabetes, hypertension, or hyperlipidemia medication in the 6 months before surgery with a corresponding diagnosis. The study found that when compared with sleeve gastrectomy, gastric bypass was associated with a slightly higher 5-year cumulative incidence of medication discontinuation among 30,588 patients with diabetes medication use and diagnosis at the time of surgery, 5,081 patients with antihypertensive medication use and diagnosis at the time of surgery and 35,055 patients with lipid-lowering medication use and diagnosis at the time of surgery. Among the patients who discontinued medication, gastric bypass was also associated with a slightly lower incidence of medication restart up to 5 years after discontinuation. The researchers concluded that gastric bypass was associated with a slightly higher incidence of medication discontinuation and a slightly lower incidence of medication restart among patients who discontinued medication than sleeve gastrectomy.
AHRQ-funded; HS025778; HS025365.
Citation: Howard R, Chao GF, Yang J .
Medication use for obesity-related comorbidities after sleeve gastrectomy or gastric bypass.
JAMA Surg 2022 Mar;157(3):248-56. doi: 10.1001/jamasurg.2021.6898..
Keywords: Obesity, Obesity: Weight Management, Surgery, Medication
Bramante CT, Buse J, Tamaritz L
Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity.
This study investigated whether outpatient metformin use is associated with reduced severity of COVID-19 in adults with overweight or obesity. Metformin can decrease interleukin-6 and tumor-necrosis factor- α, which appears to contribute to COVID-19 mortality. The authors conducted a retrospective cohort analysis of electronic health record (EHR) data that was pooled across multiple EHR systems from 12 hospitals and 60 primary care clinics in the Midwest between March and December 2020. Inclusion criteria included data for BMI > 25 kg/m(2); age range 30-85 years; and a positive SARS-CoV-2 polymerase chain reaction test. Metformin was associated with a decrease in mortality from COVID-19 and a nonsignificant decrease in hospital admission in the overall cohort.
AHRQ-funded; HS026379.
Citation: Bramante CT, Buse J, Tamaritz L .
Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity.
J Med Virol 2021 Jul;93(7):4273-79. doi: 10.1002/jmv.26873..
Keywords: COVID-19, Infectious Diseases, Obesity, Medication, Treatments, Outcomes
Gurka MJ, Siddiqi SU, Filipp SL
Attention deficit hyperactivity disorder medications and BMI trajectories: the role of medication type, sex and age.
Investigators estimated the proximal change in BMI associated with start of medication and to assess whether medication-specific departures in BMI varied by age and sex in patients with attention deficit hyperactivity disorder (ADHD). Longitudinal electronic health records from children aged 4-19 years with an ADHD diagnosis at one healthcare system were analyzed. They found that all medications had larger impacts at younger ages; decreased BMI was observed with stimulants, while antidepressants and antipsychotics led to BMI increases as did alpha-agonists, significantly varying by sex and age. They recommended future research to study further the interactions of these medications on long-term impacts on obesity.
AHRQ-funded; HS025298.
Citation: Gurka MJ, Siddiqi SU, Filipp SL .
Attention deficit hyperactivity disorder medications and BMI trajectories: the role of medication type, sex and age.
Pediatr Obes 2021 Apr;16(4):e12738. doi: 10.1111/ijpo.12738..
Keywords: Children/Adolescents, Behavioral Health, Medication, Obesity
Yaramala SR, McElroy SL, Geske J
The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study.
Lithium and quetiapine can cause weight gain, but their comparative longer term anthropometric effects are unknown, as are the potential moderating effects of baseline binge-eating (BE) behavior. In this research, the investigators assessed 6 month changes in body weight, body mass index (BMI) and waist circumference in 482 adults with DSM-IV bipolar disorders who participated in a comparative effectiveness study of lithium and quetiapine with evidence-based adjunctive treatment (Bipolar CHOICE).
AHRQ-funded; HS019371.
Citation: Yaramala SR, McElroy SL, Geske J .
The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study.
months of treatment: Findings from the bipolar CHOICE study.
J Affect Disord 2020 Apr 1;266:772-81. doi: 10.1016/j.jad.2018.09.025.
.
J Affect Disord 2020 Apr 1;266:772-81. doi: 10.1016/j.jad.2018.09.025.
.
Keywords: Behavioral Health, Medication, Obesity, Comparative Effectiveness, Patient-Centered Outcomes Research, Evidence-Based Practice, Outcomes
Bourgi K, Jenkins CA, Rebeiro PF
Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
This study compared weight gain among persons with HIV (PWH) following different antiretroviral therapy (ART) drug classes. The cohort was part of the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). The 22,972 participants were 87% male and 41% white. Twenty percent started strand transfer inhibitor (INSTI), 31% started protease inhibitor (PI), and 49% started non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based ART. Average weight gain was higher with INSTI-based regimens compared to NNRTI-based regimens or PI-based regimens.
AHRQ-funded; 90047713.
Citation: Bourgi K, Jenkins CA, Rebeiro PF .
Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
J Int AIDS Soc 2020 Apr;23(4):e25484. doi: 10.1002/jia2.25484.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Obesity: Weight Management, Obesity, Medication
Smith ME, Lee JS, Bonham A
Effect of new persistent opioid use on physiologic and psychologic outcomes following bariatric surgery.
In this study, the investigators sought to determine the relationship between new persistent opioid use and 1-year postoperative outcomes for patients undergoing bariatric surgery. The investigators concluded that new persistent opioid use is common following bariatric surgery and associated with significantly worse physiologic and psychologic outcomes. More effective screening and postoperative surveillance tools are needed to identify these patients, who likely require more aggressive counseling and treatment to maximize the benefits of bariatric surgery.
AHRQ-funded; HS024403.
Citation: Smith ME, Lee JS, Bonham A .
Effect of new persistent opioid use on physiologic and psychologic outcomes following bariatric surgery.
Surg Endosc 2019 Aug;33(8):2649-56. doi: 10.1007/s00464-018-6542-0..
Keywords: Opioids, Surgery, Medication, Obesity: Weight Management, Obesity, Obesity: Weight Management, Pain, Outcomes
Grant MC, Gibbons M M, Ko CY
Evidence review conducted for the Agency for Healthcare Research and Quality Safety Program for Improving Surgical Care and Recovery: focus on anesthesiology for bariatric surgery.
The authors conducted an evidence review to select anesthetic interventions that positively influence outcomes and facilitate recovery after bariatric surgery. They summarize the best available evidence to recommend the anesthetic components of care for enhanced recovery after bariatric surgery. The concluded that there is evidence in the literature, and from society guidelines, to support AHRQ’s Safety Program for Improving Surgical Care and Recovery goals for bariatric surgery.
AHRQ-funded; 233201500020I.
Citation: Grant MC, Gibbons M M, Ko CY .
Evidence review conducted for the Agency for Healthcare Research and Quality Safety Program for Improving Surgical Care and Recovery: focus on anesthesiology for bariatric surgery.
Anesth Analg 2019 Jul;129(1):51-60. doi: 10.1213/ane.0000000000003696..
Keywords: Evidence-Based Practice, Medication, Obesity, Outcomes, Patient-Centered Outcomes Research, Patient Safety, Quality Improvement, Surgery
Brownley KA, Berkman ND, Peat CM
Binge-eating disorder in adults: a systematic review and meta-analysis.
This review summarized evidence about the benefits and harms of psychological and pharmacologic therapies for adults with binge-eating disorder. It concluded that cognitive behavioral therapy, lisdexamfetamine, SGAs, and topiramate reduced binge eating and related psychopathology, and lisdexamfetamine and topiramate reduced weight in adults with binge-eating disorder.
AHRQ-funded; 290201200008U.
Citation: Brownley KA, Berkman ND, Peat CM .
Binge-eating disorder in adults: a systematic review and meta-analysis.
Ann Intern Med 2016 Sep 20;165(6):409-20. doi: 10.7326/m15-2455.
.
.
Keywords: Obesity, Medication, Evidence-Based Practice, Behavioral Health, Comparative Effectiveness
Allaire BT, Raghavan R, Brown DS
Morbid obesity and use of second generation antipsychotics among adolescents in foster care: evidence from Medicaid.
The researchers examined the association between receiving a morbid obesity diagnosis and second generation antipsychotics (SGAs) prescriptions among adolescents in foster care. They found that the risk increases with age. Quetiapine and clozapine increased the risk of a morbid obesity diagnosis more than 2.5 times, and two or more psychotropic drugs (polypharmacy) increased the risk fivefold.
AHRQ-funded; HS020269.
Citation: Allaire BT, Raghavan R, Brown DS .
Morbid obesity and use of second generation antipsychotics among adolescents in foster care: evidence from Medicaid.
Child Youth Serv Rev 2016 Aug;67:27-31. doi: 10.1016/j.childyouth.2016.05.019.
.
.
Keywords: Medicaid, Obesity, Medication, Children/Adolescents, Risk
Mansi I, Frei CR, Wang CP
Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults.
The authors studied the long-term relationship between statin use and new-onset diabetes among Tricare beneficiaries. They found that diabetes, diabetic complications, and overweight/obesity were more commonly diagnosed among statin-users than similar nonusers in a healthy cohort of adults, demonstrating that short-term clinical trials might not fully describe the risk/benefit of long-term statin use for primary prevention.
AHRQ-funded; HS022418.
Citation: Mansi I, Frei CR, Wang CP .
Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults.
J Gen Intern Med 2015 Nov;30(11):1599-610. doi: 10.1007/s11606-015-3335-1.
.
.
Keywords: Adverse Drug Events (ADE), Diabetes, Medication, Obesity
Daubresse M, Alexander GC
The uphill battle facing antiobesity drugs.
The authors argue that the barriers faced by individual anorectic products belie larger regulatory and clinical challenges to their mainstream adoption, and contribute to the irony that despite American’s penchant for high rates of pharmaceutical use, obesity drugs have fared remarkably poorly in the market.
AHRQ-funded; HS0189960.
Citation: Daubresse M, Alexander GC .
The uphill battle facing antiobesity drugs.
Int J Obes 2015 Mar;39(3):377-8. doi: 10.1038/ijo.2014.169..
Keywords: Obesity, Medication, Obesity: Weight Management, Policy
Raebel MA, Newcomer SR, Bayliss EA
Chronic opioid use emerging after bariatric surgery.
The purpose of this study was to determine opioid use the year after bariatric surgery among patients who did not use opioids chronically pre-surgery and to identify pre-surgery characteristics associated with chronic opioid use after surgery. It found that patients dispensed 60 to 119 days’ supply during the pre-surgery year were 13.23 to 14.29 times more likely to use opioids chronically post-surgery than patients without opioid use pre-surgery.
AHRQ-funded; HS019912.
Citation: Raebel MA, Newcomer SR, Bayliss EA .
Chronic opioid use emerging after bariatric surgery.
Pharmacoepidemiol Drug Saf 2014 Dec;23(12):1247-57. doi: 10.1002/pds.3625..
Keywords: Medication, Obesity, Opioids, Pain, Substance Abuse, Surgery
Sarpong EM
AHRQ Author: Sarpong EM
The impact of obesity on medication use and expenditures among nonelderly adults with asthma.
The author examined the impact of obesity on medication use and expenditures among nonelderly adults with asthma using the Medical Expenditure Panel Survey. He found that obese classes II/III individuals were more likely to have current asthma, seek treatment for asthma, use more medications, and have higher medication and health care expenditures compared with normal weight individuals. His results suggested that reduction in body weight may help reduce health resource use and expenditures for nonelderly adults with asthma.
AHRQ-authored.
Citation: Sarpong EM .
The impact of obesity on medication use and expenditures among nonelderly adults with asthma.
J Health Care Poor Underserved 2014 Aug;25(3):1245-61. doi: 10.1353/hpu.2014.0142.
.
.
Keywords: Asthma, Healthcare Costs, Medical Expenditure Panel Survey (MEPS), Medication, Obesity
Raebel MA, Newcomer SR, Reifler LM
Chronic use of opioid medications before and after bariatric surgery.
This study of 11,179 obese patients receiving bariatric surgery found that among the 933 who were using opioids chronically before bariatric surgery, 77 percent continued chronic opioid use in the year following surgery (excluding the first 30 days after surgery). The amount of chronic opioid use was greater postoperatively than preoperatively.
AHRQ-funded; HS019912
Citation: Raebel MA, Newcomer SR, Reifler LM .
Chronic use of opioid medications before and after bariatric surgery.
JAMA. 2013 Oct 2;310(13):1369-76. doi: 10.1001/jama.2013.278344..
Keywords: Medication, Obesity, Opioids, Pain, Substance Abuse, Surgery